Results 111 to 120 of about 10,598 (216)

NTRK gene fusions in non-small cell lung carcinomas and its correlation with other somatic mutations

Medicine Science
NTRK gene fusions are rare but actionable oncogenic drivers of non-small cell lung cancer (NSCLC). Although receptor tyrosine kinase (TRK) inhibitors show high efficacy, the relationship between NTRK status, concurrent mutations, and immune biomarkers ...
Zeynep Sagnak Yilmaz, Zeynep Turkmen Usta, Gizem Teoman, Rumeysa Beyzanur Gulcebi, Sevdegul Aydin Mungan, Safak Ersoz   +5 more
doaj   +1 more source

NTRK amplification occurs frequently in pan-TRK immunopositive dedifferentiated liposarcomas [PDF]

The neurotrophic tyrosine kinase receptor (NTRK) gene family is of rising importance as their fusions are oncogenic, and specific target drugs are available to inhibit the chimera proteins.
Károly Szuhai, Gergő Papp, Johanna Sápi, Zoltán Sápi, Katalin Dezső, Zoltán Lippai   +5 more
core   +1 more source

NTRK fusion-positive cancers and TRK inhibitor therapy

, 2018
NTRK gene fusions involving either NTRK1, NTRK2 or NTRK3 (encoding the neurotrophin receptors TRKA, TRKB and TRKC, respectively) are oncogenic drivers of various adult and paediatric tumour types.
Drilon, Alexander, Maurizio Scaltriti, Alexander Drilon, Scaltriti, Maurizio, Cocco, Emiliano, Emiliano Cocco   +5 more
core   +1 more source

NTRK-rearranged spindle cell tumor with SPECC1L-NTRK3 fusion in the thoracic spine: a case report

Journal of Cancer Research and Clinical Oncology
Neurotrophic Tyrosine Receptor Kinase (NTRK)-rearranged spindle cell tumors are a category of soft tissue tumors characterized by rearrangements of the NTRK gene family (NTRK1, NTRK2, and NTRK3), which leads to distinct molecular genetics, morphological,
Mi Zhou, Huaiyuan Xu, Jianxiong Niu, Qibing Yang, Anqi Wang, Hao Wu, Xiangqin Wang, Meng Yang, Jinxin Hu, Qinglian Tang, Jin Wang   +10 more
doaj   +1 more source

Early‐Phase Research in Pediatric Neuro‐Oncology

Pediatric Blood &Cancer, Volume 73, Issue 10, October 2026.
Jonathan Cunningham
wiley   +1 more source

ERK signaling promotes resistance to TRK kinase inhibition in NTRK fusion-driven glioma mouse models

Cell Reports
Summary: Pediatric-type high-grade gliomas frequently harbor gene fusions involving receptor tyrosine kinase genes, including neurotrophic tyrosine kinase receptor (NTRK) fusions.
Sebastian Schmid, Zachary R. Russell, Alex Shimura Yamashita, Madeline E. West, Abigail G. Parrish, Julia Walker, Dmytro Rudoy, James Z. Yan, David C. Quist, Betemariyam N. Gessesse, Neriah Alvinez, Kimberly D. Hill, Larry W. Anderson, Patrick J. Cimino, Debra K. Kumasaka, Ralph E. Parchment, Eric C. Holland, Frank Szulzewsky   +17 more
doaj   +1 more source

Case report: Adult NTRK-rearranged spindle cell neoplasms with TPM3-NTRK1 fusion in the pelvic

Frontiers in Oncology
NTRK-rearranged spindle cell neoplasms (NTRK-RSCNs) are rare soft tissue tumor molecularly characterized by NTRK gene rearrangement, which occurs mostly in children and young adults, and rarely in adults. The abnormal tumor located in superficial or deep
Qiurui Cao, Zhifang Huang, Hong Liang, Xing Hu, Lucas Wang, Yaxian Yang, Bin Lian, Jian Huang, Jinyan Guo   +8 more
doaj   +1 more source

A Case Report of Lung Adenocarcinoma with EGFR G719A Mutation 
and LMNA-NTRK1 Fusion

Chinese Journal of Lung Cancer
Fusion variations of neurotrophic receptor tyrosine kinase (NTRK) are oncogenic drivers in various solid tumors such as breast cancer, salivary gland carcinoma, infant fibrosarcoma, etc.
Shiqi SONG, Yaxian YANG, Weiquan LUO, Yueya LIANG, Qi LI, Tongxu ZHUO, Weibin XIONG, Jian HUANG   +7 more
doaj   +1 more source

Challenges in the Diagnosis of NTRK Fusion-Positive Cancers [PDF]

Journal of Thoracic Oncology, 2020
Gautschi O, Bubendorf L, Leyvraz S, Menon R, Diebold J   +4 more
openaire   +3 more sources

High prevalence of NTRK fusions in sporadic dMMR/MSI mCRC RAS/RAF wild-type: an opportunity for a post-immune checkpoint inhibitors progression rescue strategy

ESMO Gastrointestinal Oncology
Background: Currently, mismatch repair deficient/microsatellite instable (dMMR/MSI) status constitutes a validated predictive marker of response to immune checkpoint inhibitors (ICIs) in patients with metastatic colorectal cancer (mCRC).
M. Svrcek, A. Cayre, T. Samaille, R. Colle, L. Mas, P. Bourgoin, E. Guillerm, R. Cohen, F. Penault-Llorca, T. André, N. Radosevic-Robin   +10 more
doaj   +1 more source